MO01.27 Three-Year Follow-up of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, As Second-Line (2L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)